Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical trial

Journal of Clinical Microbiology

Volumn 44, Issue 7, 2006, Pages 2579-2580

  Ghannoum, M ^a   Isham, N ^a   Sheehan, D ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GRISEOFULVIN; VORICONAZOLE;

ARTICLE; COLONY FORMATION; DERMATOPHYTE; DRUG SENSITIVITY; MICROSPORUM CANIS; MICROSPORUM GYPSEUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TINEA CAPITIS; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON TONSURANS; TRICHOPHYTON VIOLACEUM;

ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; CLINICAL TRIALS; FLUCONAZOLE; GRISEOFULVIN; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TINEA CAPITIS; TRIAZOLES;

EID: 33746211150     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00818-06     Document Type: Article

References (11)

1. Barry, A. L., M. A. Pfaller, R. P. Rennie, P. C. Fuchs, and S. D. Brown. 2002. Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob. Agents Chemother. 46:1781-1784.
2. Clinical and Laboratory Standards Institute. 2001. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline-second edition. CLSI document M23-A2. Clinical and Laboratory Standards Institute, Wayne, Pa.
3. Clinical and Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. CLSI document M38-A. Clinical and Laboratory Standards Institute, Wayne, Pa.
4. Elewski, B. 1999. Treatment of tinea capitis: beyond griseofulvin. J. Am. Acad. Dermatol. 40(6, Pt. 2):S27-S30.
5. Foster, K. W., S. F. Friedlander, H. Panzer, M. A. Ghannoum, and B. E. Elewski. 2005. A randomized controlled trial assessing the efficacy of fluconazole in the treatment of pediatric tinea capitis. J. Am. Acad. Dermatol. 53(5):798-809.
6. Ghannoum, M., N. Isham, R. Hajjeh, M. Cano, F. Al-Hasawi, D. Yearick, J. Warner, L. Long, C. Jessup, and B. Elewski. 2003. Tinea capitis in Cleveland: survey of elementary school students. J. Am. Acad. Dermatol. 48(2):189-193.
7. Ghannoum, M. A., V. Chaturvedi, A. Espinel-Ingroff, M. A. Pfaller, M. G. Rinaldi, W. Lee-Yang, and D. W. Warnock. 2004. Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes. J. Clin. Microbiol. 42:2977-2979.
8. Jessup, C. J., J. Warner, N. Isham, I. Hasan, and M. A. Ghannoum. 2000. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J. Clin. Microbiol. 38:341-344.
9. Mohrenschlager, M., H. P. Seidl, J. Ring, and D. Abeck. 2005. Pediatric tinea capitis: recognition and management. Am. J. Clin. Dermatol. 6(4):203-213.
10. Norris, H. A., B. E. Elewski, and M. A. Ghannoum. 1999. Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilution method. J. Am. Acad. Dermatol. 40(6, Pt. 2):S9-S13.
11. Ogasawara, Y., J. Hara, M. Hiruma, and M. Muto. 2004. A case of black dot ringworm attributable to Trichophyton violaceum: a simple method for identifying macroconidia and microconidia formation by Fungi-Tape and Myco-Perm-Blue. J. Dermatol. 31(5):424-427.